Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
复制标题
DOI：
10.1002/cyto.b.21249
复制
发表时间：
2016-01
期刊：
影响因子：
--
通讯作者：
Rawstron AC
中科院分区：
文献类型：
--
作者：
Stetler-Stevenson M;Paiva B;Stoolman L;Lin P;Jorgensen JL;Orfao A;Van Dongen J;Rawstron AC
流式细胞术（FC）检测多发性骨髓瘤（MM）的微小残留病（MRD）是预后和对治疗反应的预测。因此，FC MM MRD检测的标准化对于确保更好和统一的治疗反应评估和临床预后至关重要。国际临床细胞术学会和欧洲临床细胞分析学会认识到标准化FC方法的必要性，组织了一个工作组来制定FC MM MRD良好临床实践的共识指南。对标本质量、染色过程、试剂组合和数据采集过程提出了一致的指导方针，这些都是实现高质量FC MM MRD测试的关键因素。一组8名流式细胞仪目前在MM中进行FC检测，评估了FC MM MRD检测的现有文献。制定了一份介绍最佳做法的文件，并进行了连续几轮的审查，直至达成协商一致意见。在MM中检测MRD的最佳实践中，共识是CD38、CD138和CD45与CD19、CD56、CD27、CD81和CD117联合分析。制定了可接受的标本质量、染色程序、面板设计和数据采集的共识指南。关键词：骨髓瘤；微小残留病；流式细胞术
Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing. A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached. The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. Key terms: myeloma; minimal residual disease; flow cytometry
登录
查看更多内容
影响因子：
20.3
作者：
Nowakowski, GS;Witzig, TE;Rajkumar, SV
通讯作者：
Rajkumar, SV
影响因子：
45.3
作者：
Mateo, Gema;Montalban, M. Angeles;Miguel, Jesus F. San
通讯作者：
Miguel, Jesus F. San
影响因子：
3.4
作者：
Jasper, Gregory A.;Arun, Indu;Stetler-Stevenson, Maryalice
通讯作者：
Stetler-Stevenson, Maryalice
影响因子：
2.2
作者：
O'Hara, Denise M.;Xu, Yuanxin;Litwin, Virginia
通讯作者：
Litwin, Virginia
影响因子：
11.4
作者：
Kalina, T.;Flores-Montero, J.;van der Velden, V. H. J.;Martin-Ayuso, M.;Boettcher, S.;Ritgen, M.;Almeida, J.;Lhermitte, L.;Asnafi, V.;Mendonca, A.;de Tute, R.;Cullen, M.;Sedek, L.;Vidriales, M. B.;Perez, J. J.;te Marvelde, J. G.;Mejstrikova, E.;Hrusak, O.;Szczepanski, T.;van Dongen, J. J. M.;Orfao, A.
通讯作者：
Orfao, A.